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Abstract 
Background: Heart failure (HF) is a chronic condition where the heart cannot pump enough 
blood to adequately oxygenate cells.  The CardioMEMS HF device is implanted into the 
pulmonary artery (PA) allowing practitioners to monitor pressures remotely and prescribe 
interventions.       
Objectives: The primary purpose of this project was to determine if CardioMEMS is an effective 
intervention in the reduction of hospital admissions, emergency department (ED), and clinic 
visits for HF patients.  The secondary purpose was to determine if the quality of life (QOL) and 
exercise tolerance was improved post-implant. 
Methods: The author conducted a retrospective chart review by accessing previously compiled 
data for patients with the CardioMEMS device to evaluate the number of hospital admissions, 
emergency, and clinic visits pre and post-implant.  Patients completed the Minnesota Living with 
Heart Failure Questionnaire to determine if their QOL improved. Pre and post 6-minute walk test 
(6MWT) data was reviewed to evaluate exercise tolerance.   
Results: The CardioMEMS HF device shows potential to decrease acute inpatient care needs 
and improve QOL for HF patients.   Hospital admissions for HF were significantly reduced post 
implant (p= 0.020). Self-reported QOL scores significantly improved post-CardioMEMS implant 
(p<0.0001).  There was a non-significant trend towards decreased ED (p= 0.292) and clinic visits 
(p=0.438) post-CardioMEMS implant. Comparison of changes in 6MWT was inconclusive.   
Conclusion: The CardioMEMS HF device appears to be a valid option to help minimize acute 
care needs of HF patients while improving QOL for most.  More research is needed to determine 
effectiveness of CardioMEMS device for exercise tolerance.         
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Evaluation of CardioMEMS Heart Failure Device 
Problem Statement 
With obesity rates rising and numerous comorbidities facing the nation, the risk for 
chronic conditions is at an all-time high.  These chronic conditions put a strain on the healthcare 
system by contributing to avoidable hospital admissions, increased emergency department (ED) 
and clinic visits. Additionally, patient readmissions within 30 days after hospitalization further 
strain the healthcare system and are an indicator of the quality of patient care.  The decrease in 
reimbursement rates that hospitals receive from the government and private insurance providers 
is an avoidable organizational consequence of preventable hospital readmissions.   
Of six conditions that are noted for the highest hospital readmission rates, heart failure 
(HF) patients were more likely than any other patients to be readmitted within 30 days of 
discharge (Hines, Barrett, Jiang, & Steiner, 2014).  According to a recent article, HF 
readmissions cost an average of $13,000 per case and accounted for roughly 25% of all 
readmissions (Hines, et al., 2014).   
Beyond the straining of resources, chronic conditions can take a toll on patients' 
perceived quality of life (QOL).  HF is a chronic condition where the heart muscle weakens 
making it difficult to pump oxygenated blood through the body.  This leads to fatigue, shortness 
of breath, and difficulty performing activities of daily living (ADLs).  There is no cure for HF, 
only symptom control with medications, weight checks, and lifestyle changes (AHA, 2017). 
Purpose 
The primary purpose of this project was to conduct a retrospective chart review to 
determine if the implantable device, CardioMEMS is an effective intervention in the reduction of 
hospital admissions, ED visits, and clinic visits for HF patients.  To achieve this, the author 
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examined hospital admission, ED, and unscheduled clinic visit data before and post-implant for 
patients with the CardioMEMS device.  The secondary purpose of this project was to determine 
if HF patients’ perceived QOL improved after implementation of the CardioMEMS device.  
Patients’ self-reported scores on the Minnesota Living with Heart Failure Questionnaire 
(MLHFQ) were obtained to measure QOL.  The 6-minute walk test (6MWT), a simple measure 
for aerobic exercise tolerance, was conducted pre and post-CardioMEMS implant to evaluate the 
effectiveness of the implant for improving exercise tolerance.   
Research Questions: 
1. Was there a significant difference in LOS, acuity of condition, and number of hospital 
admissions, emergency department (ED), and clinic visits in patients diagnosed with HF 
before and after receiving CardioMEMS implant?   
2. Was there an improvement in the HF patients’ perceived QOL after receiving the 
CardioMEMS HF device?   
3. Is there a significant increase in 6-minute walk distance in HF patients post-
CardioMEMS implant compared with pre-implant? 
Specific Aims 
1. Perform a retrospective chart review to determine if the CardioMEMS device is an 
effective intervention to reduce hospital admissions, acuity of the condition, length of 
stay, ED visits, and clinic visits for HF patients.  
2. Administer the MLHFQ to determine if the CardioMEMS HF device has improved 
the perceived QOL after obtaining the implant.   
3. Compare existing 6MWT data pre and post-CardioMEMS implant to determine if 
there is an improvement in exercise tolerance. 
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Background 
HF is a chronic, progressive condition where the heart muscle is unable to pump enough 
blood through the body to adequately oxygenate cells, leading to shortness of breath, fatigue, and 
at times, coughing.  Currently, there is no cure for HF with the only option to control symptoms 
by using medication and lifestyle changes (AHA, 2017).   
According to the American Heart Association (AHA), the prevalence of HF in America is 
on the rise with approximately 900,000 new diagnoses each year.  As of 2014, 6.5 million people 
were living with HF compared with 5.7 million people just two years prior.  HF is the leading 
cause of hospitalization in adults over 65 years of age (AHA, 2017).  In 2014, the prevalence of 
HF in Medicare patients was 11%, yet 34% of all Medicare/Medicaid healthcare cost can be 
attributed to HF patients, while 42% of Medicare admissions are for HF (Fitch, Pelizzari, & 
Pyenson, 2015).  HF patients account for 55% of all hospital readmissions and cost three times as 
much as other diagnoses (Fitch, et al., 2015).           
Another factor to consider is the impact HF admissions have on hospitals across the 
country.  With the implementation of the Affordable Care Act (ACA) in 2010, hospitals are 
facing financial penalties for 30-day hospital readmissions (Kripalani, Theobald, Anctil, & 
Vasilevskis, 2014).  With readmission penalties reaching an all-time high, 2014 estimates put the 
total amount that Medicare will withhold at more than half a billion dollars and providers are 
struggling to reduce hospital readmission rates (Kripalani, et al., 2014). Reducing avoidable 
readmissions is also a key goal for the Centers for Medicare & Medicaid (CMS).  Patients under 
active readmission prevention programs are more likely to have an improved functional status 
and QOL (Sheingold, Zuckerman, & Shartzer, 2016).  
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Failure to successfully transition patients from inpatient to outpatient care results in 
readmission to the hospital.  When this failure occurs, it is a violation of the Institute for Health 
Improvement's (IHI) Triple Aim initiative.  According to the article by Hitch et al. (2016), the 
IHI's Triple Aim is to improve the quality of care, improve the health of populations, and reduce 
cost.  Healthcare systems that have a high percentage of patients with 30-day hospital 
readmissions, neglect to improve the quality of care, improve the health of populations, and 
reduce costs (Hitch et al., 2016).   
It is beneficial to reduce hospital admissions, along with ED, and clinic visits to improve 
overall health and QOL for HF patients.  CardioMEMS, a device developed by Abbott, is an 
intervention that may improve HF patient outcomes (Abraham et al., 2011).  CardioMEMS is an 
implantable device that allows practitioners to remotely monitor the pulmonary artery (PA) 
pressure of HF patients.  The device is inserted during a standard right heart catheterization as 
part of an outpatient procedure by accessing the femoral artery using a sheath, with the 
CardioMEMS inserted over a guide wire, and finally deployed in the pulmonary artery.  
Literature Review 
            The author conducted a review of the literature to evaluate the use of the CardioMEMS 
HF implantable device related to decreased hospitalizations, ED, and clinic visits, in addition to 
improved QOL and exercise tolerance.  The CardioMEMS device is an intervention that was 
approved by the Food and Drug Administration (FDA) to monitor the pulmonary artery (PA) 
pressure of select HF patients.  The wireless implant transmits data to a secure database that 
allows clinic and medical professionals to view and interpret the patient's PA pressures.  Data 
sent from the device to clinics providing follow up care to patients with the device allows for 
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implementation of proactive measures to keep HF patients out of the hospital and emergency 
departments, as well as reduce clinic visits (St. Jude Medical, 2016).   
Several studies have evaluated the effect of CardioMEMS on hospital readmission rates 
in HF patients.  The landmark CHAMPION study, the first of its kind, monitored CardioMEMS 
recipients from 2005 to 2011 (Abraham et al., 2011).  The purpose of the study was to determine 
the long term-safety and efficacy of the CardioMEMS HF device.  The authors achieved this by 
following 550 HF patients that received the CardioMEMS implant in comparison with 120 
control patients without the device from 64 sites across the United States.   
Abraham et al. (2011) recognized that despite current treatments and interventions, 
admission rates for HF patients have remained unchanged.  Many patients admitted to the 
hospital with congestive heart failure (CHF) exacerbation could benefit from earlier detection.  
This congestion results in elevated pulmonary artery (PA) pressures.  The CardioMEMS is an 
implantable device that monitors patients' PA pressures, which elevates weeks before 
hospitalization is necessary.  The CardioMEMS device sends PA pressures remotely to clinics so 
that closer monitoring of HF patients can take place.  The study found that there was a reduction 
of 37% of hospital readmissions in the treatment group versus the control group.  The limitation 
listed for this study was the challenge of potentially unmasking patients.  According to the 
authors, the research was funded by CardioMEMS (Abraham, et al., 2011).     
Similarly, Davidovich et al. (2017) performed a retrospective chart review of 119 patients 
with the CardioMEMS HF device from four different hospital sites in Minnesota and South 
Dakota to determine if CardioMEMS HF device was an effective intervention to decrease 
hospital admissions.  The researchers retrospectively reviewed charts from a cohort of 119 HF 
patients who received the CardioMEMS implant and concluded that emergency room visits and 
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hospitalizations were reduced in HF patients that had CardioMEMS.  The study showed a post-
CardioMEMS implant decrease in HF hospital admissions from 187 to 36 and ED visits for HF 
from 1110 to 616 in the first year post-implant (Davidovich, et al., 2017). 
Additionally, Kanat and Nichols (2017) performed an analysis of 34 HF patients with 
CardioMEMS implants at a hospital in Northern California to determine the effectiveness of 
CardioMEMS in reducing healthcare utilization and hospital admission rates.  This retrospective 
chart review examined the medical records of 34 patients with CardioMEMS implant for the 12 
months before and after the device was implanted.  The data revealed that 17 of the 34 patients 
with the CardioMEMS FH device had no hospital admissions in the year post-implant compared 
to pre-implant data of 69 total hospital visits.  This data helped the authors to conclude that the 
CardioMEMS HF device has a positive impact on hospital admission rates for HF patients that 
have received the CardioMEMS device.  The authors neglected to discuss limitations, conflict of 
interest, or funding information in their research paper (Kanat & Nichols, 2017).     
To further add to the evidence, Ratham, Unruh, Nissley, Nissley, and Roberts (2016) 
conducted a post-implant retrospective review of 21 patients with CardioMEMS implants 
between February 2015 and October 2015 to evaluate HF related hospital admissions.  The 
researcher found on average hospital admissions reduced from two to 0.6 per year for patients 
with the implant.  They also concluded that CardioMEMS is the first HF diagnostic tool to 
positively impact hospitalizations in HF patients with preserved ejection fraction.  There were no 
limitations, conflict of interest declaration, or information about how the study was funded 
(Ratham, et al., 2016).           
To evaluate the actual physiological impact, Heywood et al. (2017) reviewed 
CardioMEMS data of 2000 patients with the device from all over the United States.  Data was 
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collected directly from St. Jude Medical database.  The database is a patient care network where 
device driven data is managed and stored.  The purpose of this database is to allow caregivers to 
view data from devices such as the CardioMEMS HF device and pacemakers in order to make 
clinical decisions (St. Jude Medical, 2018).  The researchers' purpose was to establish a data 
review separate from previously conducted clinical trials.  They found through a retrospective 
chart review that patients with CardioMEMS had significantly lower PA pressure after the 
device was implanted versus before implantation, which lead to fewer HF exacerbations needing 
intervention (Heywood, et al., 2017). 
The CardioMEMS HF device has been shown to be a cost-effective way to manage HF 
patients.  By utilizing a Markov model, a way to predict or forecast future events, Schmier, Ong, 
and Fonarow (2017), were able to determine the cost-effectiveness for the CardioMEMS device 
versus the current standard of care.  The model compared outcome data over five years for those 
with CardioMEMS HF device versus the current standard of care for patients with HF. The study 
included the cost of having the device implanted, cost of monitoring the patient and of 
subsequent hospitalizations for HF.  The authors concluded that the CardioMEMS device 
improved quality-adjusted life year (QALY) over the standard of care thus demonstrating the 
device cost effective (Schmier, et al., 2017). 
 Overall, the literature supported the use of CardioMEMS in HF patients to help manage 
HF symptoms and exacerbations.   Most of the articles reviewed had small sample sizes because 
the CardioMEMS HF device received FDA approval in May of 2014 meaning the pool of 
recipients is rather small.  Several articles also neglected to include limitations, conflict of 
interest declarations, and how the research was funded.  All the articles showed a decrease in the 
number of hospital admissions for HF patients with the CardioMEMS device.  What is not clear 
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from conducting the literature review is if CardioMEMS HF device leads to an improved QOL 
and better daily functionality and exercise tolerance.  With this study, the author hoped to add a 
better understanding of how the CardioMEMS device improves both QOL and exercise tolerance 
while keeping HF patients out of the hospital and ED.       
Significance  
Evaluation of the CardioMEMS data collected on HF patients that receive care at the 
Heart and Vascular Clinic was conducted to reveal whether or not the device contributed to 
decreased hospitalizations, ED visits, and clinic visits in this sample.  Few studies have evaluated 
QOL and 6MWT in patients after receiving the CardioMEMS implant. The MLHFQ 
questionnaires were given to the HF patients at Heart and Vascular Clinic to determine if there 
were differences in the perceived QOL for HF patients with the CardioMEMS device pre and 
post-implant.  Data obtained from 6MWT completed at the clinic both pre and post-implant were 
also conducted to reveal if having the CardioMEMS device improved exercise tolerance.  The 
data analyzed in this project may help clinicians understand if the CardioMEMS device reduces 
hospitalization and improves exercise tolerance and overall QOL of HF patients.           
The medical center has trialed several programs for HF patients in the past to reduce 
hospital admission rates for HF patients with little success.  These interventions include 
discharge follow-up calls to HF patients, providing resources such as scales and logs for tracking 
daily weights, medications and blood pressures.  This project intended to determine if there is a 
significant decrease in hospitalization, ED, and clinic visits in HF patients with the 
CardioMEMS device.  Findings from this project may identify a viable intervention to help 
hospitals reduce cost and increase reimbursement rates by keeping HF patients out of the 
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hospital.  Reaching out to patients with CardioMEMS HF device can identify potential issues, 
patients can be referred to their primary care provider, and prevent admission to the hospital.    
Gaps in Knowledge 
At the time the research was conducted, heart and vascular clinic did not know if the 
CardioMEMS HF device has any impact on decreasing hospital admissions, ED, or clinic visits 
or if it improves the QOL for HF patients.  The heart and vascular clinic along with the medical 
center had been collecting data on HF patients that have the CardioMEMS device, but analysis of 
the data had yet to occur making it impossible to determine the effectiveness of the device.  This 
research study extracted and examined data so that it could be determined if the CardioMEMS 
device reduces hospitalizations and improves the QOL of those that have received the implant.  
Findings from this project helped to determine if the intervention is useful for improving HF 
patient outcomes.   
If the CardioMEMS device proves to be effective in reducing hospital admissions, ED 
visits, and clinic visits for HF patients, it could be an essential cost-saving intervention.  At the 
time the research was conducted, the medical center had placed the CardioMEMS implantable 
device in 19 patients, but the data had not been analyzed to determine if this was a useful 
intervention for HF patients.       
Theoretical Foundation  
The theoretical framework that supported this project is the Analyze, Design, Develop, 
Implement, and Evaluate (ADDIE) model.  This model was an instructional design that helped 
formulate solutions to a given problem through a five-step process, including an in-depth 
Analysis, Design, Development, Implementation, and Evaluation of the research questions and 
overall project (McGriff, 2000).  The ADDIE model was particularly useful when applied to this 
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research project, as data analysis is the key to determine the next step in the process.  This model 
was a valuable tool for planning, implementation, and evaluation of this research project (See 
appendix for ADDIE diagram). 
The author applied ADDIE to the research questions to help guide the analysis and 
evaluation of CardioMEMS implants in HF patients and its impact on the patients that have 
received the device.  During the design and development phase, the author made decisions 
regarding what the study design was going to be and developed the research questions and how 
best to obtain answers.  After receiving IRB approval, implementation of the study began which 
consisted of gaining a waiver of consent from patients and administering the MLHFQ.  This 
model also assisted in keeping the research on track by referring to the steps at different stages of 
the proposal development.  During all phases, evaluation takes place, formative while the 
research study is ongoing and a cumulative evaluation occurred at the end of the study to provide 
the conclusion and recommendations.     
Variables 
Defining the dependent, independent, confounding and clinical variables was a crucial 
step to help examine all the factors that contribute to whether the CardioMEMS device was an 
effective intervention to reduce the number of times that patients with HF seek care (See Table 
1).  The dependent variables were hospital admissions, acuity of the condition, length of stay, ED 
visits, clinic visits for HF exacerbation, MLHFQ, and 6MWT.  The author conducted a 
retrospective review of patient data to determine the precise number of patients with the 
CardioMEMS device admitted to the hospital or who sought care for HF complication one year 
prior and one-year post-implant.  The MLHFQ was collected retrospectively due to the Clinic 
not conducting this questionnaire before device deployment. 
EVALUATION OF CARDIOMEMS  13 
 
The independent variable is the CardioMEMS implantable device.  It was necessary to 
include diagnosis date, date of CardioMEMS implant and the number of hospital admissions, 
ED, and clinic visits one-year prior and one-year post-implant for HF complications. 
The confounding variables affected hospitalizations and reasons for seeking care for 
complications of HF.  The author documented what interventions if any, the provider prescribed 
to help keep patients out of the hospital or from obtaining care in the ED or clinic. Two other 
clinical factors that could influence how well a patient did post-discharge include the 
hospitalization admit diagnosis, comorbidities, and the acuity of the patient.  The author 
collected demographic data as well, including age, race, gender and marital status.   
Research Design 
The author utilized a retrospective chart review to determine if CardioMEMS was an 
effective intervention for decreasing the frequency of, length of stay, and acuity of hospital 
admissions, ED, and clinic visits for HF-related symptoms or conditions.  The data reviewed 
spanned one year prior and one-year post-implant that the Medical Center and the Heart and 
Vascular Clinic collected during the normal day-to-day operations.  A pre and post-study design 
was used to determine if the self-reported QOL for patients with the CardioMEMS implant 
improved post-procedure by collecting the MLHFQ.  The author also conducted a review of the 
6MWT data collected by the heart and vascular clinic pre and post-implant. 
Study Population  
The target population for this project was HF patients with the CardioMEMS implant.   
The available sample was HF patients at a tertiary care center in the Pacific Northwest and the 
heart and vascular clinic operated by the medical center, who received the CardioMEMS 
implant.  This author contacted the patients that have the CardioMEMS device and receive 
EVALUATION OF CARDIOMEMS  14 
 
follow-up care at the heart and vascular clinic via telephone to obtain consent to participate in the 
study.  After a brief introduction, the author administered two MLFHQ.  The patients were able 
to participate in the study by answering both questionnaires, reflecting how they rate their QOL 
pre and post-CardioMEMS implant.  Inclusion criteria were as follows; participants must have 
the CardioMEMS device and receive outpatient care at the heart and vascular clinic and inpatient 
care from the medical center, and consent to be included in the study.  Excluded cases included 
all patients that have not received the CardioMEMS implant or are no longer receiving care at 
the heart and vascular clinic, those who declined to participate, patients that the author was 
unable to reach via telephone, or those that were deceased.  
Sample Size 
At the time this research was conducted 19 patients were participating in the 
CardioMEMS program and receiving follow-up care at the heart and vascular clinic.  Of the 19 
patients, 18 qualified to participate in this research study.  The author was able to obtain consent 
for chart review and complete 14 MLHFQ surveys of the 18 eligible patients.   
Setting  
This study took place in a community-based, not-for-profit, tertiary care facility that 
consists of four separate hospitals that care for HF patients.  In 2012 the medical center, affiliated 
with another larger hospital system to become one of the largest healthcare providers in the 
Pacific Northwest and Alaska.  At the time of writing this report, the medical center remained a 
distinct entity responsible for the day-to-day operations including human resource affairs and 
separate union representation.  The two organizations share the same financial and patient 
outcome goals.  Patients included in the study all received follow-up care at the heart and 
vascular clinic operated by the medical center. 
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Intervention 
CardioMEMS is an implantable, hemodynamic monitoring device manufactured by St. 
Jude Medical Inc. The manufacturer's data show that the device reduces hospital admissions for 
HF patients (St. Jude Medical, 2016).  An interventional cardiologist inserts the CardioMEMS 
HF device into the pulmonary artery (PA) during a standard right heart catheterization.  After 
deployment of the device, it begins sending PA pressures to a secure server.  The device sends 
alerts to the provider if the set PA mean trends higher for three consecutive days.  Once alerted, 
the provider can contact the patient with interventions, such as adjusting medication or fluid 
restrictions to help reach the ideal PA meanwhile avoiding hospitalization and Emergency Room 
visits (St. Jude Medical, 2016).    
Measuring Variables and Operational Definition 
The independent variable is having the CardioMEMS HF device implanted.  The 
dependent variables include perceived QOL, exercise tolerance, admission to the hospital, ED 
visits, and clinic visits for HF symptoms or exacerbation.  The author defined the confounding, 
covariant, and clinical variables and listed them in the variable table in the appendix.  See table 
one in the appendix for a complete list of variables. 
Measurement Tools 
Exercise tolerance was measured using the 6MWT.  Bellet, Adams, and Morris, 2012, 
conducted an extensive literature review to determine if the 6MWT was a reliable and valid tool 
to assess exercise tolerance in cardiac patients.  The authors concluded that the literature review 
found the 6MWT demonstrated strong test–retest reliability (intra-class correlation coefficient = 
0.97) between repeated 6MWT.  As for the validity, the authors were unable to determine due to 
limited research and literature available (Bellet, et al., 2012).   
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Uszko-Lencer et al. (2017) conducted a retrospective observational study to determine if 
6MWT was reliable and valid as a prognostic tool for HF patients.  The 6MWT is a valuable tool 
for many conditions to assess daily functionality.  The test consists of the patient walking on a 
hard, flat surface for six minutes or as long as tolerated, whichever comes first.  The authors 
determined that the distance traveled in that time can be a predictor of mortality and increased 
risk of hospitalizations.  The researchers concluded that 6MWT is a reliable and valid tool to 
measure daily functionality (Uszko-Lencer, et al., 2017).         
Uszko-Lencer et al. (2017) determined the 6MWT was reliable (ICC = 0.90, P < 0.0001). 
The learning effect was 31 m (95%CI 27, 35 m).  To test the reliability of 6MWT, the two-way 
random intra-class correlation coefficient with single measures (ICC2, 1) was calculated.  The 
paired t-test was used to test differences between two 6MWT. The unpaired t-test, one-way 
ANOVA, or chi-square was used to compare groups.  The authors determined that the 6MWT 
was reliable and valid in patients with mild-to-moderate HF (Uszko-Lencer et al., 2017).    
The MLHFQ was used to measure patient’s self-reported QOL. Mogel, Buck, Zambroski, 
Alvaro, and Vellone (2016) conducted a cross-sectional study to determine if the MLHFQ 
showed cultural bias.  The authors concluded that some questions on the survey might vary 
depending on the geographical location, but it does not affect the validity of the questionnaire.  
Cultural influences are often at play.  Researchers should acknowledge these influencers when 
utilizing the MLHFQ (Mogel, et al., 2016). 
The questionnaire consists of 21 questions addressing the physical, emotional, and 
socioeconomic aspect of HF.  Questions are scored zero through five, with zero being no impact 
and five which very much affects QOL.  The score range is 0-105.  To determine the impact of 
the score Behlouli, et al., 2009, assigned a numeric range to determine HF patients as having 
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good, moderate or poor QOL.  A total score of < 24 on the MLHFQ denotes a good QOL, a 
score between 24 and 45 signifies a moderate QOL, and a score > 45 represents a poor QOL.  
The authors found that these ranges correlated with survival rates, self-perceived health status, 
New York Health Association (NYHA) functional class, and 6MWT (Behlouli, et al., 2009).       
Supino et al., 2009, determined the reliability and validity of the MLHFQ by conducting 
the questionnaire with 47 valve replacement patients.  The authors found the Cronbach's α was 
≥0.9 (total score, dimensions), supporting internal reliability was high for the MLHFQ. The 
secondary analysis confirmed the MLHFQ for physical/emotional domain items (relative chi-
squares <3.0, critical ratios >2.0, both instruments), supporting structural validity. Spearman 
coefficients correlating MLHFQ with parallel SF-36 domains were moderate to high (0.6-0.9; P 
≤ .001: T 0 -T 2), supporting convergent validity (Supino et al., 2009).     
Data Collection 
This project utilized previously collected data through a retrospective chart review of HF 
patients that have the CardioMEMS device.  Data extraction included hospitalizations, for 
patients that were admitted to the hospital with a diagnosis or complication related to HF, ED 
visits, and clinic visits, as well as, demographic variables.  The author reviewed data from 
records at both the Heart and Vascular Clinic and all inpatient facilities within the organization. 
Given that the organization managed the data, it helped ensure that the author was reviewing up-
to-date and accurate information.   
Another way to substantiate this claim was that the organization is responsible for 
collecting and submitting accurate data to the Center for Medicare and Medicaid to be compliant 
with the laws put forth by the Affordable Care Act.  Data collection and management adhered to 
the standards set forth by the organization and were in compliance with HIPAA laws.  As 
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previously stated, the data was accessible via the EMR.  Protecting patients' identities was of 
utmost importance.   The author ensured confidentiality by assigning each patient subject 
numbers as identifiers; no names were available in this format.   
To complete the MLHFQ with patients that received the CardioMEMS implant, the 
author called each patient via telephone.  The author used a recruitment script to inform patients 
as to the nature of the study, voluntary participation, and to ensure each patient that maintaining 
their confidentiality was a priority.  The 6MWT was completed in the clinic both pre and post-
implant and was available as previously collected data.  The author utilized a retrospective chart 
review to collect the data with the exception of the MLHFQ questionnaire. 
Timeline  
A Gantt chart was constructed to show the timeline for this study.  This chart helped the 
author stay on track and focus on the next steps of the paper.  SPSS 23 software and Microsoft 
Excel spreadsheets were used to store, organize, and manage the compiled data.  A copy of the 
Gantt chart is in the appendix of this paper.  
Data Analysis Plan 
This project consisted of a retrospective chart review along with questionnaires 
administered to patients with the CardioMEMS HF implant to determine if the device is an 
effective intervention to improve QOL and reduce hospital admissions, ED visits, and clinic 
visits for patients diagnosed with HF.  The author analyzed data that was collected previously by 
the organization's quality department and maintained in the patient’s electronic medical record.  
To determine if there were patterns to the data the author reviewed frequency tables according to 
descriptive variables such as age, sex, and diagnosis.  To establish whether there was statistical 
significance, a paired sample t-test was conducted to compare if there was a significant 
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difference in the number of ED visits, hospitalizations, and clinic visits pre and post-
CardioMEMS HF device implantation.   
To determine if CardioMEMS HF device improved the QOL for its recipients the author 
administered the MLHFQ to patients with the CardioMEMS device that sought care at the Heart 
and Vascular Clinic.  The recipients completed two questionnaires, recalling their QOL pre-
implant and also reflecting on how they feel post-implant.  The author then conducted a paired 
samples t-test to determine if there is a significant difference in self-reported perceived QOL 
before and after CardioMEMS implant. 
With the questionnaires being subjective, it was important to look objectively at whether 
patients have improved exercise tolerance pre and post-implant.  The author reviewed the 6MWT 
data that the Heart and Vascular Clinic collected pre and post-CardioMEMS implant to 
determine objectively whether the patient’s exercise tolerance had improved.  Again, the author 
conducted a paired sample t-test to determine if these patients had improved exercise tolerance 
after the CardioMEMS implant. 
  After compiling the dataset, relevant statistics such as the mean, standard deviation, and 
range for continuous variables and descriptive statistics such as percentages and frequencies for 
categorical variables were generated.  Due to the small sample size, the author utilized 
descriptive statistics to identify trends.  After examining the data, the author decided a paired t-
test was warranted.  Assuming an effect size of 0.70 (Cohen's d), a power of 75% (0.75), and a 
type 1 error rate (alpha) of 0.05, 14 participants were required to conduct a paired samples t-test 
with a one-tailed test of significance (Plichta, 2013).   
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Ethical Considerations 
To comply with Institutional Review Board (IRB) standards and the guidelines put forth 
by the Health Insurance Portability and Accountability Act (HIPAA), protection of patient 
identities is of utmost importance.  As stated above, the author ensured confidentiality by using 
unique subject numbers as identifiers rather than names and age range instead of specific 
birthdays.  The author entered and stored all information into approved hospital software and 
saved it on a USB drive inspected and permitted by the organization.  The author ensured active 
firewalls and encryption along with password protection to help keep data secure and reduce the 
vulnerability of the system.  The author maintained transparency by operating within the IRB 
approval and seeking an amendment when changes or corrections became necessary.  Only the 
researchers approved by the IRB had access to the data compiled for this study.  Both the 
Medical Center and the George Washington University IRB reviewed and approved the study. 
Results 
Demographics.  After collecting the retrospective chart review data and completing the 
MLHFQ the author compiled the data into the codebook.  Next, the data was entered into the 
SPSS software developed by IBM to examine descriptive statistics and determine if the results 
were statistically significant.  Descriptive characteristics for the participants according to age, 
gender, race, marital status, alcohol, tobacco and drug use are presented in Table 2.  The 
demographic breakdown for patients included in this study was collected to help identify trends 
if they exist.  The study included ten males and four females.  Five patients are Black and nine 
are Caucasian.  Five patients are married and nine are single.  Of the 14 patients, one is between 
the ages of 50-59, five are 60-69, seven are 70-79, and one is 80-89. 
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Lifestyle choices.  Along with demographic information, the author obtained a history 
and current use of tobacco containing products, substance abuse, and alcohol use through the 
chart review process.  None of the patients identified as currently using tobacco products, 
however, eight patients are former smokers.  Two patients responded that they use recreational 
marijuana, as it is legal in Washington State.  Four patients drink one to two servings of alcohol 
per week.  
Hospital admissions, ER, and clinic visit data.  To answer the research question, was 
there a significant difference in the number of hospital admissions, ER, and clinic visits in 
patients diagnosed with HF before and after receiving CardioMEMS implant, the author 
conducted a retrospective chart review.  Of 14 patients in the study, two patients had the same 
number of hospital admissions post-CardioMEMS implant versus pre-implant while two patients 
had more hospital admissions.  Three patients had more ER visits post-CardioMEMS when 
compared to pre-implant data, with seven patients having the same number of visits both pre and 
post-implant.  Two patients had increased clinic visits for HF post-CardioMEMS implant versus 
pre-implant, with three patients demonstrating the same number both pre and post-implant.  
Please see figure 1 in the appendix to see a comparison of the patient outcomes before and after 
CardioMEMS implant.  
Statistical analysis.  Analysis of the data using a paired t-test showed that the mean 
number of hospital admissions for HF related causes or symptoms was significantly reduced 
after the CardioMEMS implant compared with pre-implant hospitalizations (p= 0.020).  There 
were 25 total hospital admissions pre-implant versus nine post-implant for the sample of 
participants.  There was not a significant difference between the pre and post mean number of 
ED visits (p= 0.292), however there was a trend in the data that supports a decrease in the total 
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number of ED visits post-implant.  There were a total of 11 ED visits pre-implant versus six 
post-implant for HF related causes or symptoms among the patients in the sample.  The mean 
number of pre and post-implant clinic visits were also not significantly different (p=.438), but 
again, the trend in the data suggests fewer clinic visits post-implant.  There were a total of 96 
clinic visits related to HF causes or symptoms pre-implant versus 70 post-implant for the patients 
in this sample.  Table 3 in the appendix shows the means, standard deviations and paired t-test 
results for pre and post CardioMEMS implant hospital admissions, ED visits, unplanned clinic 
visits and MLHFQ scores.     
Comorbidities.  To gain a complete understanding of the potential impact that the 
CardioMEMS HF device could have on patients living with HF, it was essential to consider what 
and how many comorbidities each patient had in addition to HF.  The patients included in this 
study all had at least one comorbidity with ten comorbidities being the most.  See Table 4 in the 
appendix for a detailed list of comorbidities and the number of patients effected. 
Interventions.  Another consideration is what interventions were prescribed by the clinic 
in order to maintain acceptable PA wedge pressures.  Interventions ranged from adding, 
increasing, and decreasing diuretics, having patients go to the clinic for IV diuretics, and 
increasing weight checks.  Of note, three patients required no intervention in the year that 
proceeded the device deployment.  Four patients had hospital admissions for HF symptoms and 
exacerbation.  All patients’ acuity level was determined to be fair.  Length of stay (LOS) for each 
admission ranged from one to seven days.   
  MLFHQ data and statistical analysis.  The next research question, was there an 
improvement in the HF patients’ perceived QOL after receiving the CardioMEMS HF device, 
required the author to contact patients via telephone to conduct the MLHFQ.  At the point of 
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contact, verbal consent was obtained for the chart review portion of the study.  Of the 18 eligible 
patients, 14 gave consent for chart review, and 13 were able to complete the questionnaire.  The 
results of the MLHFQ showed that two patients had no reported change in QOL pre-implant 
versus post-implant, while 11 reported a positive change in QOL after receiving the 
CardioMEMS HF device.  Please see figure 2 in the appendix for the graph of the MLHFQ 
results.  A paired t-test demonstrated that overall, the mean MLHFQ scores were significantly 
improved for patients after receiving the CardioMEMS implant (p<0.0001). See Table 3 in the 
appendix for the paired t-test results.  
 6MWT data and statistical analysis.  The final research question, is there a significant 
increase in 6-minute walk distance in HF patients post-CardioMEMS implant compared with 
pre-implant, required the author to review patients charts to determine if the CardioMEMS 
device improved exercise tolerance in HF patients.  The chart review showed that of the 14 
patients only three had both pre and post-walk distances recorded, while the remaining 11 only 
stated that the 6MWT was complete.  Because of this, the author was unable to determine 
whether the CardioMEMS HF device improves exercise tolerance in HF patients.  
Discussion 
 The purpose of this study was to determine if the CardioMEMS HF device decreased the 
acute need for patients to seek care for HF symptoms or conditions while improving the QOL 
and exercise tolerance of HF patients that received the CardioMEMS device.  The study took 
place at a tertiary care center in the Pacific Northwest and the heart and vascular clinic operated 
by the medical center.  The program included 19 patients of which 18 were eligible to participate 
in the study.  The author was able to make contact with, obtain verbal consent from 14 patients, 
and complete 13 MHLQ surveys.  
EVALUATION OF CARDIOMEMS  24 
 
The data collected from the chart review and MLHFQ was entered into a codebook for 
further analysis.  The paired t-test showed that the average number of hospital admissions were 
significantly decreased after receiving the CardioMEMS implant.  The decrease in admissions 
could be attributed to early intervention when wedge PA pressures rise.  The findings of this 
study correlate with the literature reviewed, which found less frequent hospitalization for HF 
symptoms or exacerbation post-CardioMEMS implant (Abraham, et al., 2011; Davidovich, et al., 
2017; Kanat & Nichols, 2017; Ratham, et al., 2016; & Schimer, et al., 2017).  
 Largely, the results of this analysis found no significant differences in ED visits pre and 
post implant, but did show a trend towards reduced ED visits.  The author was unable to find 
literature that compared ER visits pre and post-CardioMEMS implant. 
 Overall there were no significant differences in the mean number of clinic visits before 
and after CardioMEMS implant, but there was a trend towards fewer visits.  When comparing 
clinic visits for HF pre and post-CardioMEMS implant, the author noted that one patient had 
significantly more clinic visits post-implant.  Upon further chart review, it was determined that 
the patient had moved to the area shortly before the CardioMEMS was implanted, this could 
explain why the patient had thirteen more clinic visits post-implant versus pre-implant.  Three 
patients had the same number of clinic visits pre and post-implant.  Nine patients had fewer 
clinic visits post-CardioMEMS implant versus pre-implant.  The group of patients that had fewer 
clinic visits post-implant had a mean of three, a median of two, and mode of one.  The author 
was unable to find literature that compared clinic visits pre and post-CardioMEMS implant. 
 The author conducted the MLHFQ via telephone with 13 of the 18 eligible HF patients 
that received the CardioMEMS HF device (p= 0.292).  Of the 13 patients, two reported no 
change, while 12 reported a positive change in their perceived QOL.  Four of the patients 
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reported only moderate improvement in QOL post-implant.  Those that perceived a change in 
QOL from poor pre-implant to good post-implant consisted of four patients.  The remaining 
three patients stated a change in QOL from moderate pre-implant to good post-implant.  One 
participant was unable to answer the questionnaire due to a time constraint on their end but did 
give the author permission to conduct the chart review.  The author was unable to find any 
literature that compared perceived QOL ratings for patients pre and post-CardioMEMS implant 
and to the author’s knowledge this is the first study to use the MLHFQ to evaluate the 
effectiveness of the CardioMEMS implant to improve QOL. 
 Unfortunately, the results of the 6MWT comparison from the pre-CardioMEMS implant 
to post were inconclusive due to documentation inconsistencies at the clinic.  Of the 14 patients, 
three had both pre and post-implant results.  Two were unchanged, and one patient was able to 
tolerate an additional 10 meters when comparing times pre and post-implant.  The author was 
unable to find literature that compared 6MWT pre and post-CardioMEMS implant. 
 After reviewing the data, the author has determined that the CardioMEMS HF device 
shows potential to decrease the acute care needs and improve the perceived QOL of HF patients.  
Further research is needed to understand the impact that the CardioMEMS device has on exercise 
tolerance.  Studies that include larger patient samples will be necessary to corroborate the 
findings of this research study. 
Limitations 
One limitation of this study is interpreting results due to the small study size.  The 
number of CardioMEMS patients eligible for the study was 18.  Fourteen patients agreed to 
participate which is a small sample and the statistical power of the study could be improved with 
a larger sample.   
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Another limitation is the MLHFQ that was administered to patients required them to give 
self-reported, retrospective opinions on their QOL.  This could influence the study by 
participants giving false, misleading, or incomplete answers.  Also, the author read the questions 
aloud to participants and unintentional biases such as inflection or emphasize on certain words 
could influence the participant to respond to the questions.   
It is important to consider that due to the comorbidities of several patients it was difficult 
for them to speak directly to HF as the cause for decreased QOL.  Some patients were unable to 
participate in the 6MWT due to physical limitations caused by factors including but not limited 
to HF such as chronic anemia, back, and sciatica pain.  
The 6MWT data was not documented for all patients before and post-CardioMEMS HF 
device implant.  For this reason, the author is unable to determine whether there was a significant 
increase in 6-minute walk distance in HF patients post-CardioMEMS implant compared with 
pre-implant.  Not having the data is an unfortunate situation as it is an important metric to 
determine exercise tolerance. 
Lastly, due to a few patients joining the clinic practice shortly before the CardioMEMS 
implant, data for hospital admissions, ER, and clinic visits does not allow for a complete clinical 
picture.  Not having this data could skew the results to show that the devices do not appear as 
useful for two of the patients.   
Implications/Recommendations 
 The implications for practice is that the CardioMEMS HF device is useful for monitoring 
and earlier intervention that has the potential to decrease acute care needs in patients with HF, 
this in turn, can lead to fewer hospital admissions, ER, and clinic visits.  For healthcare 
EVALUATION OF CARDIOMEMS  27 
 
organizations this could have an enormous impact that frees up resources and perhaps capital as 
the need for readmission is no longer a factor.   
Patients included in this research study reported either no difference or a positive change 
in their perceived QOL.  Healthcare continues to move toward preventative medicine and for 
patients already dealing with a chronic condition such as HF the use of technology to help 
prevent more healthcare encounters can be life-changing.  The CardioMEMS HF device has the 
potential to positively impact the QOL of HF patients.  More research is needed with a larger 
sample size to determine if the CardioMEMS device is indeed a useful tool to decrease acute 
healthcare needs, improve QOL, and improve exercise tolerance.   
Conclusion 
 In conclusion, the CardioMEMS device shows potential to decrease the acute care needs 
for HF patients.  MLHFQ results also revealed the possibility of improving QOL.  Unfortunately, 
the results of the exercise tolerance test were inconclusive as the chart review revealed all but 
three patients did not have a distance recorded, just a note that read the 6MWT was complete. 
 Further research may determine the exact impact on acute care needs, QOL, and 6MWT.  
This study served to start the discussion and to find what could be done to manage HF patients 
more proactively.  The CardioMEMS device appears to be a valid option for those patients that 
demonstrate reliability and comply with any necessary interventions prescribed by the care team 
from the clinic.       
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Appendix 
MINNESOTA LIVING WITH HEART FAILURE QUESTIONNAIRE 
  
The following questions ask how much your heart failure (heart condition) affected your life 
during the past month (4 weeks).  After each question, circle the 0, 1, 2, 3, 4 or 5 to show how 
much your life was affected.  If a question does not apply to you, circle the 0 after that question.  
  
Did your heart failure prevent   
you from living as you wanted during                              Very                            Very  
the past month (4 weeks) by -                                 No      Little                           Much   
              
1. Causing swelling in your ankles or legs?        0            1        2        3        4        5  
2. Making you sit or lie down to rest during      
the day?                     0            1        2        3        4        5  
3. Making your walking about or climbing          
stairs difficult?                  0            1        2        3        4        5  
4. Making your working around the house          
or yard difficult?                 0            1        2        3        4        5  
5. Making your going places away from                 
home difficult?                   0            1        2        3        4        5  
6. Making your sleeping well at night       
difficult?                     0            1        2        3        4        5  
7. Making your relating to or doing things   
with your friends or family difficult?             0            1        2        3        4        5  
8. Making your working to earn a living       
difficult?                     0            1        2        3        4        5                                      
9. Making your recreational pastimes, sports      
or hobbies difficult?                    0            1        2        3        4        5  
10. Making your sexual activities difficult? 0            1        2        3        4        5  
11. Making you eat less of the foods you like?    0            1        2        3        4        5  
12. Making you short of breath?                           0            1        2        3        4        5  
13. Making you tired, fatigued, or low on         
energy?                     0            1        2        3        4        5  
14. Making you stay in a hospital?    0            1        2        3        4        5 
15. Costing you money for medical care?            0            1        2        3        4        5  
16. Giving you side effects from treatments?       0            1        2        3        4        5       
17. Making you feel you are a burden to your          
family or friends?                                           0            1        2        3        4        5 
18. Making you feel a loss of self-control          
in your life?                       0            1        2        3        4        5   
19. Making you worry?                     0            1        2        3        4        5  
20. Making it difficult for you to concentrate          
or remember things?                     0            1        2        3        4        5   
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Table 1. Variable list 
 
Variable Theoretical Definition Operational Definition Measurement Tool/Data 
Collection Methodology 
Dependent 
Variable 
Admissions to 
the hospital 
Admitted to the 
hospital for symptoms 
or conditions related to 
HF. 
Yes = 1 
No=0 
  
Chart audits 
Dependent 
Variable 
ED visits 
ED visits for symptoms 
or conditions related to 
HF. 
Yes=1 
No=0 
Chart audits 
Dependent 
Variable 
Clinic visits 
Clinic visits for 
symptoms or 
conditions related to 
HF. 
Yes=1 
No=0 
Chart audits 
Dependent 
Variable 
MLHFQ 
completion 
Completed 
questionnaires. 
Yes=1 
No=0 
Tool: MLHFQ 
 
Phone calls to patient by 
this author. 
Dependent 
Variable 
QOL pre-
implant  
What was the total self-
reported QOL score 
pre CardioMEMS 
implant? 
 
Pre-implant score=Total 
score on MLHFQ 
Tool: MLHFQ 
 
Phone calls to patient by 
this author. 
 
Dependent 
Variable 
QOL post- 
implant 
What was the total self-
reported QOL score 
post-CardioMEMS 
implant? 
Post-implant 
score=Total score on 
MLHFQ 
Tool: MLHFQ 
 
Phone calls to patient by 
this author. 
Dependent 
Variable 
6MWT 
improvement 
Was there an 
improvement in 
exercise tolerance? 
Yes=1 
No=0 
Tool: 6MWT 
 
Chart audit 
Dependent 
Variable 
6MWT pre 
implant 
What was the distance 
the patient can walk in 
6 minutes pre implant? 
Pre-implant 6MWT= 
Total distance walked in 
meters and centimeters 
in 6 minutes. 
Chart audit 
Dependent 
Variable 
6MWT post-
implant 
What was the distance 
the patient can walk in 
6 minutes post-
implant? 
Post-implant 6MWT= 
Total distance walked in 
meters and centimeters 
in 6 minutes 
Chart audit 
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Independent 
variable 
CardioMEMS 
implant 
Does patient have 
CardioMEMS implant? 
Yes=1 
No=0 
Chart audit 
Confounding 
variable 
Comorbidities  
Number of other 
chronic conditions the 
patient has been 
diagnosed with having. 
 
One= 1 
Two= 2 
Three= 3 
Four= 4 
Multiple (> 5)= 5 
Chart audit 
Confounding 
variable 
Interventions 
Intervention prescribed  
 
 
None= 0 
Weight check=1 
Add diuretic= 2 
Increase diuretic= 3 
Decrease diuretic= 4 
Stop diuretic= 5 
IV diuretic in clinic= 6 
Chart audit 
Confounding 
variable 
Compliance 
Was the patient 
compliant with the 
intervention? 
Yes=1 
No=0 
Chart audit 
Confounding 
variable 
Tobacco use 
Patient current or 
previous tobacco use 
Yes=1  
No=0 
Chart audit 
Confounding 
variable 
Alcohol use 
Patient current or 
previous alcohol use 
Yes=1 
No=0 
Chart audit 
Confounding 
variable 
Substance 
abuse 
 
Patient current or 
previous abuse of 
prescription or illicit 
drugs  
Yes=1 
No=0 
Chart audit 
Clinical 
variable 
Admitting 
diagnosis 
Patient main reason 
for/ diagnosis during 
hospitalization 
Specific diagnosis that 
required admission to 
the hospital 
Chart audit 
  
Clinical 
variable 
Length of stay 
(LOS) 
 
Amount of time patient 
was in the hospital.  
0-2 midnights= 1  
3-5 midnights= 2 
6-8 midnights= 3 
 
Chart audit 
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Clinical 
variable 
Acuity 
The condition of the 
patient at admission to 
the hospital. 
0= Undetermined: The 
patient’s condition was 
unknown at this time. 
1= Good: The patient’s 
vital signs and overall 
condition was stable. 
2= Fair: The patient’s 
current condition was 
stable but there is a 
chance of deterioration.  
3= Serious: The patient 
was very ill, and might 
have had unstable vital 
signs and overall 
condition is concerning. 
4= Critical: The patient 
had unstable vitals and 
indicators for recovery 
were unfavorable. 
Chart audit 
Demographic       
Gender Biologic determination 1. Male  
2. Female 
Chart audit. 
Age Range Chronological age in 
years 
50-59= 1 
60-69= 2 
70-79= 3 
Chart audit. 
Race Classification into 
groups based on 
ancestry or genetics 
1. Black or African  
    American   
2. White  
Chart audit 
Marital Status   1. Married 
2. Single 
Chart audit 
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Table 2. Participant Demographics 
Demographic  Frequency 
(N=14) 
Percent 
 
Age  
       50-59 
       60-69 
       70-79 
       80-89 
 
     1 
                5 
                7 
                1         
 
7.1 
35.7 
50.0 
7.1 
Gender 
        Male  
        Female 
 
               10 
    4 
 
71.4 
28.6 
Race 
         African American 
         Caucasian 
 
 
    5 
    9 
 
 
35.7 
              64.3 
 
Marital Status 
       Married 
       Single 
 
   9 
               5 
 
64.3 
35.7 
Alcohol Use 
      No 
      Rarely 
      Yes 
       
 
10 
  1 
  3 
 
 
71.4 
7.1 
21.4 
 
Tobacco Use 
     Former 
     None 
      
 
 8 
 6 
 
 
57.1 
42.9 
 
Drug Use 
    None 
    Cannabis  
 
12 
 2 
 
85.7 
14.3 
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Table 3. Comparison of Patient Outcomes Pre and Post CardioMEMS implant 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Pre-CardioMEMS Post-CardioMEMS Paired t-test 
 Range M SD Range M SD t p df 
Hospital Admissions 0-4 1.79 1.12 0-3 .64 1.51 2.655 .020 13 
Emergency Room 
Visits 
0-3 .79 1.05 0-3 .43 .85 1.099 .292 13 
Unplanned Clinic 
Visits 
2-16 7.29 5.53 0-15 6.29 5.35 .801 .438 13 
Quality of Life 
(MLHFQ score) 
31-88 52.91 16.60 3-40 18.36 11.57 6.480 .000 10 
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Table 4. Comorbidities  
Comorbidities Number of patients effected  
  
Cancer 5 
TIA 2 
CVA 2 
Anemia 1 
Aortic insufficiency  1 
CKD 2 
Mitral valve regurgitation 1 
Amyloidosis 1 
Asthma 1 
PAD 2 
V- Tachycardia  1 
HTN 6 
Obesity 4 
DMT ll 4 
Cardiomyopathy 4 
COPD 5 
CAD 8 
OSA 7 
Interstitial lung disease 1 
Hepatitis C 1 
Pulmonary HTN 4 
High cholesterol 5 
Hyperthyroidism 1 
Hypothyroidism 3 
A-fib 5 
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Figure 1. Patient outcomes pre and post-CardioMEMS implant 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Hospital admissions
(p=020, Range= 0-4)
ED visits
(p=.292, Range=0-3)
Clinic visits
(p=.438, range=2-16)
Pre 1.79 0.79 7.29
Post 0.64 0.43 6.29
1.79
0.79
7.29
0.64 0.43
6.29
0
1
2
3
4
5
6
7
8
Mean Number of Hospital, ED, and Clinic Visits 
for HF Patients Before and After CardioMEMS 
implant (n=14)
Pre Post
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Figure 2. MLHFQ scores for each participant pre and post-CardioMEMS implant 
 
 
 
 
1 2 3 4 5 6 7 8 9 10 11 12 13
MLFHQ score pre 65 38 88 51 46 42 48 31 67 64 35 62 45
MLFHQ score post 17 38 12 3 15 18 32 11 40 24 3 62 27
0
20
40
60
80
100
Minnesota Living with Heart Failure 
Questionnaire (MLHFQ) pre and post-implant
*Higher score correlates with poor QOL
MLFHQ score pre MLFHQ score post
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 Chart 1. Gantt chart  
 
 
 
  
 
Project Planner: Evaluation of CardioMEMS
 Period Highlight: 1
PERIODS
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Chose topic 1 5 1 4
100%
Creat PICOT 1 6 1 6
100%
Problem statement and background 4 4 4 5
100%
Significance and literature review 6 8 6 6
100%
Theoretical foundation and variables 10 2 10 8
100%
Method overview 12 3 12 6
100%
Intervention and data 14 4 14 5
100%
CITI training 18 2 18 5
100%
Procedure and timeline 22 2 22 6
100%
IRB application: Organization's IRB 26 40 26 120
100%
IRB application: GWU's IRB 50 21 50 26
100%
% Complete (beyond plan)Select a period to highlight at right.  A legend describing the charting follows.
ACTIVITY
PLAN 
START
PLAN 
DURATION
ACTUAL 
START
ACTUAL 
DURATION
PERCENT 
COMPLETE
Plan Duration Actual Start % Complete Actual (beyond plan)
